Healthcare Diagnostics / In Vitro Diagnostics (IVD)
Strategic Profile
Labs, Immunohematology and Cardiac businesses delivered consistent growth, while cost-savings initiatives drove meaningful margin expansion, positioning the company to generate substantially stronger free cash flow in 2026. The company is shifting strategic focus to Labs and non-respiratory growth areas, while acknowledging expected declines, particularly with donor screening winding down by mid-2026.
Cyborg Score Rationale
The company posted a 2025 GAAP net loss of $1.13 billion and a GAAP operating loss of $0.92 billion, driven largely by a $701 million non-cash goodwill impairment charge. QuidelOrtho's high expenses have contributed to an average operating margin of negative 6.2% over the last five years. However, adjusted EBITDA was $597 million with a 22% adjusted EBITDA margin, a 240 basis point improvement.
Top Insights
Full-year 2025 revenue was $2.73 billion, slightly below 2024, as respiratory revenue fell 20% to $402.1 million with lower COVID-19 testing
Adjusted EBITDA improved 240 basis points to 22% margin; free cash flow expected to improve by over $200 million in 2026, guiding to $120–$160 million
Q4 FY 2025 marked the third straight year of declining annual revenue and the third consecutive year of operating at a net loss
Chief Financial Officer Joseph M. Busky plans to retire effective June 30, 2026
Named Competitors
Diagnostics Portfolio — Broad diagnostic testing solutions across point-of-care and laboratory
Clinical Laboratory Products — Leading provider of clinical chemistry and immunoassay diagnostics
Diagnostic Imaging & Lab Systems — Comprehensive diagnostic solutions for laboratories and hospitals
Recent Developments
(March 2026) CFO retirement announced with June 30 transition date and advisory role continuation
(February 2026) Q4 2025 earnings beat Wall Street expectations; issued 2026 guidance of $2.7–$2.9B revenue
(February 2026) Adjusted EBITDA margin expanded 240 basis points; free cash flow guidance of $120–$160 million for 2026
Open the full interactive QuidelOrtho Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.